[Skip to Content]
[Skip to Content Landing]
May 1995

Who Should Have Hydroxyapatite Orbital Implants?

Author Affiliations

Los Angeles, Calif

Arch Ophthalmol. 1995;113(5):566-567. doi:10.1001/archopht.1995.01100050032024

HYDROXYAPATITE ORBITAL implants were approved by the Food and Drug Administration for replacement of orbital volume in enucleation and evisceration cases in 1989. A recent survey of oculoplastic surgeons suggests that hydroxyapatite implants are evolving to be the first-choice implant; they are now used in the majority of cases performed by oculoplastic surgeons.1 In reported series, the number of implants that received a motility peg is as low as 12%.2 This number may increase over time as these patients go on to have drilling; however, authors frequently report that patients are satisfied with their motility with an unpegged hydroxyapatite implant and do not request a motility peg. I do not believe that hydroxyapatite is the first-choice implant for patients who have no desire or no expectation to go forward with drilling, placing a motility peg, and designing a special receptacle prosthesis.

The rapid acceptance of hydroxyapatite orbital implants

First Page Preview View Large
First page PDF preview
First page PDF preview